Can bone loss in rheumatoid arthritis be prevented?

Osteoporosis International

Volumn 24, Issue 10, 2013, Pages 2541-2553

  Vis, M ^a   Guler Yuksel M ^b   Lems, W F ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biologics; DMARD; Erosions; Osteoimmunology; Osteoporosis; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN A; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLD SALT; GOLIMUMAB; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ZOLEDRONIC ACID;

AGE; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; BODY MASS; BONE DENSITY; BONE LESION; BONE METABOLISM; BONE RADIOGRAPHY; BONE STRENGTH; BONE TURNOVER; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE DURATION; DRUG MEGADOSE; FALL RISK; FAMILY HISTORY; FRAGILITY FRACTURE; GENDER; HIP FRACTURE; HUMAN; IMMOBILITY; LIFESTYLE; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS (TOPIC); MONOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SARCOPENIA; SIGNAL TRANSDUCTION; SPINE FRACTURE; SYSTEMATIC REVIEW (TOPIC); UPREGULATION; WNT SIGNALING PATHWAY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; RISK FACTORS;

EID: 84885433329     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2334-5     Document Type: Review

References (119)

1. Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet 373(9664):659-672
2. Sokka T, Abelson B, Pincus T (2008) Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 26(5 Suppl 51):S35-S61
3. Allaire S, et al. (2008) Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum 59(4):474-480
4. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205-2219
5. Bruynesteyn K, et al. (2005) Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 64(2):179-182
6. van der Heijde D (2000) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27(1):261-263
7. Bultink IE (2012) Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 64(1):2-8
8. Gravallese EM, et al. (1998) Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 152(4):943-951
9. Takayanagi H (2009) Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 5(12):667-676
10. Schett G, Saag KG, Bijlsma JW (2010) From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis 69(8):1415-1419
11. Seriolo B, et al. (2002) Serum osteocalcin levels in premenopausal rheumatoid arthritis patients. Ann N Y Acad Sci 966:502-507
12. Geusens P, Lems WF (2011) Osteoimmunology and osteoporosis. Arthritis Res Ther 13(5):242
13. Gravallese EM, et al. (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43(2):250-258
14. Zwerina J, et al. (2004) Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50(1):277-290
15. Shigeyama Y, et al. (2000) Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 43(11):2523-2530
16. Yeo L, et al. (2011) Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis 70(11):2022-2028
17. Mustila A, et al. (2011) Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies. Clin Exp Rheumatol 29(3):500-505
18. van der Helm-van Mil AH, et al. (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7(5):R949-R958
19. Harre U, et al. (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122(5):1791-1802
20. Fouque-Aubert A, et al. (2010) Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT. Ann Rheum Dis 69(9):1671-1676
21. Stach CM, et al. (2010) Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum 62(2):330-339
22. Rau R, Herborn G (1996) Healing phenomena of erosive changes in rheumatoid arthritis patients undergoing disease-modifying antirheumatic drug therapy. Arthritis Rheum 39(1):162-168
23. Matzelle MM, et al. (2012) Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum 64(5):1540-1550
24. Lories RJ, Luyten FP (2009) Osteoimmunology: Wnt antagonists: for better or worse? Nat Rev Rheumatol 5(8):420-421
25. Diarra D, et al. (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156-163
26. Appel H, et al. (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60(11):3257-3262
27. Garnero P, Tabassi NC, Voorzanger-Rousselot N (2008) Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol 35(12):2313-2315
28. Terpos E, et al. (2011) Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol 29(6):921-925
29. Xu S, Wang Y, Lu J, Xu J, (2012) Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int 32(11):3397-403
30. O'Brien CA, Nakashima T, Takayanagi H (2012) Osteocyte control of osteoclastogenesis. Bone. doi: 10.1016/j.bone.2012.08.121
31. Klein-Nulend J, Bakker AD, Bacabac RG, Vatsa A, Weinbaum S (2012) Mechanosensation and transduction in osteocytes. Bone. doi: 10.1016/j.bone.2012. 10.013
32. Boyesen P, et al. (2011) MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis 70(3):428-433
33. Lems WF (2007) Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum 56(11):3518-3522
34. Breban S, et al. (2012) Identification of rheumatoid arthritis patients with vertebral fractures using bone mineral density and trabecular bone score. J Clin Densitom 15(3):260-266
35. Cooper C, et al. (1992) Incidence of clinically diagnosed vertebral fractures: a population based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7(2):221-227
36. Oleksik A, et al. (2000) Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 15(7):1368-1375
37. Orstavik RE, et al. (2004) Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls. Arch Intern Med 164(4):420-425
38. Lems WF, et al. (2011) Osteopenia: a diagnostic and therapeutic challenge. Curr Osteoporos Rep 9(3):167-172
39. Rosholm A, et al. (2001) Estimation of bone mineral density by digital X-ray radiogrammetry: theoretical background and clinical testing. Osteoporos Int 12(11):961-969
40. Haugeberg G, et al. (2004) Hand cortical bone mass and its associations with radiographic joint damage and fractures in 50-70 year old female patients with rheumatoid arthritis: cross sectional Oslo-Truro-Amsterdam (OSTRA) collaborative study. Ann Rheum Dis 63(10):1331-1334
41. Forsblad-d'Elia H, Carlsten H (2011) Bone mineral density by digital X-ray radiogrammetry is strongly decreased and associated with joint destruction in long-standing rheumatoid arthritis: a cross-sectional study. BMC Musculoskeletal Disorders 12:242
42. Guler-Yuksel M, et al. (2010) Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis. Arthritis Res Ther 12(3):R96
43. Lodder MC, et al. (2004) Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 63(12):1576-1580
44. Haugeberg G, et al. (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 43(3):522-530
45. Haugeberg G, et al. (2000) Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 43(12):2776-2784
46. Gough AK, et al. (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344(8914):23-27
47. Spector TD, et al. (1993) Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 306(6877):558
48. Huusko TM, et al. (2001) Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis 60(5):521-522
49. van Staa TP, et al. (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54(10):3104-3112
50. Hooyman JR, et al. (1984) Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum 27(12):1353-1361
51. Roux C (2011) Osteoporosis in inflammatory joint diseases. Osteoporos Int 22(2):421-433
52. Felsenberg D, et al. (2002) Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17(4):716-724
53. Ismail AA, et al. (2002) Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 13(7):565-571
54. Amin S. and Grbariel S. (2011) Fracture Risk Is Increased in Young Women with Rheumatoid Arthritis. J Bone Miner Res 26 (Suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/Abstract2011.aspx
55. Jones G, et al. (2003) The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford) 42(1):6-13
56. Lee CK, et al. (2004) Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum 50(12):3831-3843
57. Wheeler DL, et al. (1995) The short- and long-term effects of methotrexate on the rat skeleton. Bone 16(2):215-221
58. Minaur NJ, et al. (2002) Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford) 41(7):741-749
59. di Munno O, et al. (2004) Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol 31(7):1305-1309
60. Kobayashi Y, et al. (2004) The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage. J Bone Miner Metab 22(4):318-328
61. Strand V, et al. (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159(21):2542-2550
62. Smolen JS, et al. (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353(9149):259-266
63. De Jong PH et al. (2013) Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 72(1):72-8
64. Hofbauer LC, et al. (2001) Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 280(1):334-339
65. Schlosberg M, et al. (1989) The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 124(5):2179-2184
66. Forre O (1994) Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group. Arthritis Rheum 37(10):1506-1512
67. Ferraccioli G, Casatta L, Bartoli E (1996) Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy. J Rheumatol 23(9):1539-1542
68. Mazzantini M, et al. (2007) Effect of cyclosporine A on bone density in female rheumatoid arthritis patients: results from a multicenter, cross-sectional study. Clin Exp Rheumatol 25(5):709-715
69. Hall TJ, et al. (1996) Gold salts inhibit osteoclastic bone resorption in vitro. Inflamm Res 45(5):230-233
70. Clark P et al. (2000) Injectable gold for rheumatoid arthritis. Cochrane Database of Systematic Reviews 1997, Issue 4. Art. No.: CD000520. doi: 10.1002/14651858.CD000520
71. Rizzoli R, et al. (2012) Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 91(4):225-243
72. Kirwan JR et al. (2007) Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD006356. doi: 10.1002/14651858.CD006356
73. Boers M, et al. (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350(9074):309-318
74. Haugeberg G, et al. (2005) Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med 165(11):1293-1297
75. Haugeberg G, et al. (2011) Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritis. Ann Rheum Dis 70(1):184-187
76. Durez P, et al. (2007) Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 56(12):3919-3927
77. Goekoop-Ruiterman YP, et al. (2008) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 58(2 Suppl):S126-S135
78. Bakker MF, et al. (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156(5):329-339
79. Guler-Yuksel M, et al. (2009) Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68(3):330-336
80. Dirven L, et al. (2011) Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: bone mineral density measurements in a multicenter randomized clinical trial. Arthritis Care Res (Hoboken) 63(12):1691-1699
81. Maini RN, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552-1563
82. Abu-Amer Y, et al. (2000) Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 275(35):27307-27310
83. Kobayashi K, et al. (2000) Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191(2):275-286
84. Nakashima T, et al. (2000) Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275(3):768-775
85. Schett G, et al. (2003) Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 48(7):2042-2051
86. Redlich K, et al. (2002) Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46(3):785-792
87. Vis M, et al. (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65(11):1495-1499
88. Seriolo B, et al. (2006) Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci 1069:420-427
89. Klareskog L, et al. (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675-681
90. Maini RN, et al. (2004) Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50(4):1051-1065
91. Weinblatt ME, et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35-45
92. Keystone EC, et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50(5):1400-1411
93. Favalli EG, et al. (2012) The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. Ther Adv Musculoskelet Dis 4(4):213-223
94. Eekman DA, et al. (2011) Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 70(2):389-390
95. Wijbrandts CA, et al. (2009) Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 68(3):373-376
96. Marotte H, et al. (2007) A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 9(3):R61
97. Guler-Yuksel M, et al. (2008) Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 67(6):823-828
98. Emery P, et al. (2009) Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 36(7):1429-1441
99. Smolen JS, et al. (2009) Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 68(6):823-827
100. Emery P, et al. (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54(5):1390-1400
101. Tak PP, et al. (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70(1):39-46
102. Boumans MJ, et al. (2012) Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis 71(1):108-113
103. Wheater G, et al. (2011) Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. Osteoporos Int 22(12):3067-3072
104. Salvin S, et al. (2010) Variation in Lumbar and Femoral BMD after Rituximab therapy in Active Rheumatoid Arthritis. Ann Rheum Dis 2010;69(Suppl3):704. Available at http://www.eular.org/
105. Emery P (2003) The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin Investig Drugs 12(4):673-681
106. Kliwinski C, et al. (2005) Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. J Autoimmun 25(3):165-171
107. Axmann R, et al. (2008) CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 67(11):1603-1609
108. Genant HK, et al. (2008) Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 67(8):1084-1089
109. Kishimoto T (2006) Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006;8 Suppl 2: p. S2
110. Hashizume M, Hayakawa N, Mihara M (2008) IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford) 47(11):1635-1640
111. Palmqvist P, et al. (2002) IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 169(6):3353-3362
112. Garnero P, et al. (2010) Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 62(1):33-43
113. Nishimoto N, et al. (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66(9):1162-1167
114. Smolen JS, Avila JC, Aletaha D (2012) Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 71(5):687-693
115. Kume K et al. (2011) Tociluzimab Monotherapy Improves Bone Mineral Density as well as Etanercept or Adalimumab Monotherapy in Rheumatoid Arthritis. An Open-Lable, Randomized Clinical study. Ann Rheum Dis 2011;70(Suppl3): p. 471
116. Bekker PJ, et al. (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19(7):1059-1066
117. Cohen SB, et al. (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58(5):1299-1309
118. Deodhar A, et al. (2010) Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 62(4):569-574
119. Jarrett SJ, et al. (2006) Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 54(5):1410-1414